Dr. Rigotti is an internationally known expert in tobacco cessation and is the Primary Investigator of the ORCA-2 Phase 3 clinical trial of cytisinicline. She is a Professor of Medicine at Harvard Medical School and Past President of both the Society of General Internal Medicine and the Society for Research in Nicotine and Tobacco. Dr. Rigotti founded and directs the Tobacco Research and Treatment Center at Massachusetts General Hospital whose mission is to develop innovative and effective smoking cessation treatments delivered in health care settings.